Company’s 36-month beta value is 1.88.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for APLT is 117.55M, and currently, short sellers hold a 15.32% ratio of that floaft. The average trading volume of APLT on June 11, 2025 was 2.16M shares.
APLT) stock’s latest price update
Applied Therapeutics Inc (NASDAQ: APLT) has seen a decline in its stock price by -4.17 in relation to its previous close of 0.39. However, the company has experienced a -1.44% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-18 that Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months, though the primary endpoint of 10MWRT at 12 months was not statistically significant (the measure has since been removed from the CMT-FOM clinical outcomes assessment based upon the results of the ACT-CMT study*) Statistically significant improvement in CMT-HI and statistically significant correlation between percent change in sorbitol and change in CMT-HI at 12 months Treatment with govorestat in CMT-SORD-Null rats demonstrated a highly statistically significant 37% (p=0.005) reduction of sorbitol in the sciatic nerve, the tissue of interest, after treatment with govorestat.Reflective of the peripheral neuropathy experienced by patients with CMT-SORD. Govorestat remains generally safe and well tolerated Company remains committed to potential NDA submission of govorestat for treatment of CMT-SORD in 2025 NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare disease, today presented full 12-month clinical results and new topline data from 18 and 24 months from the INSPIRE Phase 2/3 trial of govorestat (AT-007) for the treatment of Sorbitol Dehydrogenase (SORD) Deficiency, a subtype of Charcot-Marie-Tooth (CMT) disease, in an oral presentation at the Peripheral Nerve Society (PNS) 2025 Annual Meeting, being held May 17-20, 2025 in Edinburgh, Scotland.
APLT’s Market Performance
APLT’s stock has fallen by -1.44% in the past week, with a monthly drop of -20.02% and a quarterly drop of -29.17%. The volatility ratio for the week is 4.50% while the volatility levels for the last 30 days are 9.62% for Applied Therapeutics Inc The simple moving average for the last 20 days is -8.80% for APLT stock, with a simple moving average of -88.14% for the last 200 days.
Analysts’ Opinion of APLT
UBS, on the other hand, stated in their research note that they expect to see APLT reach a price target of $2, previously predicting the price at $13. The rating they have provided for APLT stocks is “Neutral” according to the report published on December 02nd, 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to APLT, setting the target price at $4 in the report published on November 29th of the previous year.
APLT Trading at -6.76% from the 50-Day Moving Average
After a stumble in the market that brought APLT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.52% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLT starting from Perfetti Riccardo, who sale 10,366 shares at the price of $0.44 back on Mar 04 ’25. After this action, Perfetti Riccardo now owns 890,409 shares of Applied Therapeutics Inc, valued at $4,561 using the latest closing price.
Funtleyder Leslie D., the insider of Applied Therapeutics Inc, sale 14,502 shares at $0.44 during a trade that took place back on Mar 04 ’25, which means that Funtleyder Leslie D. is holding 390,459 shares at $6,381 based on the most recent closing price.
Stock Fundamentals for APLT
Current profitability levels for the company are sitting at:
- -410.3 for the present operating margin
- 0.24 for the gross margin
The net margin for Applied Therapeutics Inc stands at -164.19. The total capital return value is set at -2.79. Equity return is now at value -83.71, with -41.81 for asset returns.
Based on Applied Therapeutics Inc (APLT), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -34.83.
Currently, EBITDA for the company is -103.87 million with net debt to EBITDA at 0.44. When we switch over and look at the enterprise to sales, we see a ratio of 17.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.00.
Conclusion
In a nutshell, Applied Therapeutics Inc (APLT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
